Emergent BioSolutions (EBS) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.80 --0%
Revenue Growth %: -45.6%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: -45.6%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $2.19, $0.07 better than the analyst estimate of $2.12. Revenue for the quarter came in at $385.2 million versus the consensus estimate of $437.93 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- KeyBanc Reiterates Overweight Rating on Brinker Int'l (EAT)
- Evercore lifts Ciena rating on AI-driven optical networking boom
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
